Law ❯ Litigation ❯ Corporate Law ❯ Securities Litigation

False Statements

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

The case focuses on allegations that Skye overstated nimacimab’s prospects following a Phase 2a failure disclosure.

Stride Investors Face Jan. 12 Deadline in Securities Class Action Over Enrollment Claims and Tech Failure

MoonLake Investors Face Dec. 15 Deadline in Securities Suits Over Sonelokimab Claims

KBR Investors Face Nov. 18 Deadline to Seek Lead Role in Securities Suit Over HomeSafe Disclosures